Neurotrophin gene augmentation by electrotransfer to improve cochlear implant hearing outcomes.
by Summer
No Comments
Overview outlines the development of therapeutics based on DNA for the treatment of hearing loss, and in particular, considers the potential for utilizing the properties recombinant neurotrophins to improve hearing cochlea (spiral ganglion) survival of neurons and repair , This potential to reduce the spiral ganglion neuron death and indeed re-grow the auditory nerve fibers have been the subject of pre-clinical evaluation sufficient for decades with a view of increasing the neural interface with cochlear implants.
It provides the context for the discussion on the development of novel means of using a cochlear implant electrode arrays for gene electrotransfer. mesenchymal perilymphatic compartments that line the cochlea can be selectively transfected with the (naked) plasmid DNA using various – based gene electrotransfer, called ‘near-field of electroporation’. This technology is able to drive the expression of brain derived neurotrophic factor ( BDNF ) in a rabbit model trial hearing, causing the regrowth of peripheral spiral ganglion cell neurites toward mesenchymla, and thus be close to the cochlear implant electrodes in the scala tympani.
This was associated with functional improvement of the cochlear implant neural interface (lower the recruitment threshold of nerve and extended dynamic range, measured using electrically – Evoked auditory brain stem response). Basis for the near-field of electroporation efficiency arises from compression of the electric field is close to conspire against cochlear implant electrodes. The area close to the array with the highest field strength is closely related to the distribution of bioreporter cells (adherent Human embryonic kidney (HEK293)) revealed the reporter green fluorescent protein (GFP) gene electrotransfer following.
Neurotrophin gene augmentation by electrotransfer to improve cochlear implant hearing outcomes.
Optimizing the parameters of gene electrotransfer using a cell-based model is closely correlated with in vitro and in vivo gene delivery results cochlea. Migration of cochlear implant electrode array-based platform that gene electrotransfer to a clinical trial for neurotrophin the cochlear implant-based improvement is supported by the availability of regulatory compliant plasmid backbone DNA mini-new (pFAR 4 ;. Free of antibiotic resistance plasmids v 4 ) that can be used to package ‘ human to materialize’ neurotrophin expression cassette.
A reporter cassette packed into pFAR 4 produced by expression of GFP prominent in the basal turn of guinea pig scalae perilymphatic. More broadly, the near-field of gene electrotransfer may lend itself to a spectrum of potential applications of DNA therapeutic benefits of titratable, local, naked DNA delivery, for enlargement of genes, gene regulation targeted strategy, or gene substitution. WST-1 test results revealed that compared with group / R EGD, the survival rate of cells was significantly higher in OGD / R group and lower MIF in OGD / R with ISO-1 group.
Description: A competitive ELISA for quantitative measurement of Human Neurotrophin 4 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Neurotrophin 4 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Neurotrophin 4 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Neurotrophin 4 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Neurotrophin 4 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Neurotrophin 4 in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: Quantitativesandwich ELISA kit for measuring Human Neurotrophin 4, NT-4 in samples from serum, plasma, cell culture supernates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitativesandwich ELISA kit for measuring Human Neurotrophin 4, NT-4 in samples from serum, plasma, cell culture supernates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Western blot assay and immunocytochemistry results revealed that the expression levels of BDNF , Bcl2, and MAP2 are significantly higher, and the level of expression of Caspase-3 and Bax were significantly lowered in the group MIF than in OGD / R group. the level of expression of BDNF , Bcl2, and MAP2 significantly lowered, and the level of expression of Caspase-3 and Bax were significantly higher in group 1 than in the ISO / OGD group R. MIF administration promoted cell survival nerves and causes a high level of expression of BDNF , MAP2, and Bcl-2 (anti-apoptotic) and the low expression levels of Caspase-3 and Bax (pro-apoptotic) in OGD / R models. this re
